Guangzhou Henovcom Bioscience Co. Ltd

Jiancun Zhang

Deyao Li

Yiqian Zhou

Lijun Zhang

Kun Wang

Yan Liu

Qi Guo

Yiwu Wu

Jufu Zhang

Yang Hu

Feng Wu

Ning Kang

Xiaoxi He

Yanhui Liu

Wanjun Tang

Yanwei Chen

Huajin You

Qingan Zou

Huixuan Chen

Chen Guo

Jiafeng Chen

Suyong Li

A novel tetrahydronaphthalene compound is provided, or a stereoisomer, a solvate, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the compound, and a use of the compound or the composition for preparing a medicament in prevention and/or treatment of a central nervous system disease, wherein the compound has a structure of formula (I), wherein each of X, Y, Z, W and R is defined as described in the present disclosure.

Tetrahydronaphthalene compounds, pharmaceutical compositions, and uses thereof

The present disclosure relates to compounds for RNA capping and uses thereof, which belong to the technical field of genetic engineering. Compounds of formula I can result in high levels of capping efficiency, and the capped mRNA exhibits a high transcription level and increased expression.

Compounds for RNA capping and uses thereof

Provided are novel heteroaromatic compound as an Autotaxin inhibitor, a pharmaceutical composition comprising the compound, and a use thereof in a treatment of a disease with a pathological feature of Autotaxin overexpression in a mammal, wherein the compound is according to formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, or mixture thereof; wherein each of R, Ar, Ar, Ar, W, Y, Z, and Cy is defined in the present disclosure.

Aromatic heterocyclic compound, and pharmaceutical composition and use thereof

Provided are a long-acting prodrug of Rasagiline, which has application in the treatment of Central Nervous System diseases such as Parkinson's disease, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected from each of Rand Ris independently selected from H, D, and alkyl; W is absent, or W is selected from (CH), wherein n is an integer selected from 1 to 15; X is absent, or X is selected from (CH), wherein m is an integer selected from 1 to 10; Y is absent, or Y is selected from &#x2014;C(&#x2550;O)NH&#x2014;, &#x2014;NHC(&#x2550;O)&#x2014;; Ris selected from substituted or unsubstituted C-Calkyl, substituted or unsubstituted C-Calkenyl, substituted or unsubstituted C-Calkynyl, substituted or unsubstituted C-Ccycloalkyl, cholane aliphatic group, &#x2014;R&#x2014;C(&#x2550;O)O&#x2014;R, &#x2014;R&#x2014;OC(&#x2550;O)&#x2014;R, &#x2014;R&#x2014;C(&#x2550;O)NH&#x2014;R, &#x2014;R&#x2014;NHC(&#x2550;O)&#x2014;R, &#x2014;R&#x2014;S(&#x2550;O)O&#x2014;Rand &#x2014;R&#x2014;OS(&#x2550;O)&#x2014;R. 

Long-acting prodrugs of rasagiline, preparing methods and uses thereof

Provided are a long-acting prodrug of Entecavir, preparation method and use thereof, wherein the prodrug of Entecavir has a structure of formula I. The prodrug of Entecavir can be released slowly, sustainably and steady, and converted to active compound of Entecavir to achieve a long-acting effect.

Long-acting prodrugs of entecavir, preparing methods and uses thereof

A cyclohexene compound and use thereof, which relates to the technical field of pharmaceutical chemistry is provided. The cyclohexene compound is the cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester group prodrug or a stereoisomer thereof. It is verified by activity assay for influenza NA that the cyclohexene compound has a great inhibiting activity against both wild-typed and drug-resistant influenza viruses, and the inhibiting activity ICof some compounds against wild-typed and drug-resistant influenza viruses is lower than 5 nM, showing significant inhibiting effect on influenza viruses. This shows that the cyclohexene compound or a pharmaceutically acceptable salt or a stereoisomer thereof has superior application prospect on preparing anti-influenza drugs, thereby providing a new drug choice for treating influenza clinically.

Cyclohexene compounds and use thereof

Growing community of inventors

Guangzhou, China

Jiancun Zhang